 |
PDBsum entry 5osk
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
437 a.a.
|
 |
|
|
|
|
|
|
|
421 a.a.
|
 |
|
|
|
|
|
|
|
123 a.a.
|
 |
|
|
|
|
|
|
|
316 a.a.
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Cell cycle
|
 |
|
Title:
|
 |
Tubulin-7j complex
|
|
Structure:
|
 |
Tubulin alpha-1b chain. Chain: a, c. Synonym: alpha-tubulin ubiquitous,tubulin k-alpha-1,tubulin alpha- ubiquitous chain. Tubulin beta-2b chain. Chain: b, d. Stathmin-4. Chain: e. Synonym: stathmin-like protein b3,rb3.
|
|
Source:
|
 |
Bos taurus. Cattle. Organism_taxid: 9913. Tissue: brain. Rattus norvegicus. Norway rat. Organism_taxid: 10116. Gene: stmn4. Expressed in: escherichia coli.
|
|
Resolution:
|
 |
|
2.11Å
|
R-factor:
|
0.197
|
R-free:
|
0.232
|
|
|
Authors:
|
 |
G.Menchon,A.E.Prota,M.O.Steinmetz,B.V.L.Potter
|
|
Key ref:
|
 |
W.Dohle
et al.
(2018).
Quinazolinone-Based Anticancer Agents: Synthesis, Antiproliferative SAR, Antitubulin Activity, and Tubulin Co-crystal Structure.
J Med Chem,
61,
1031-1044.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
17-Aug-17
|
Release date:
|
20-Dec-17
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P81947
(TBA1B_BOVIN) -
Tubulin alpha-1B chain from Bos taurus
|
|
|
|
Seq: Struc:
|
 |
 |
 |
451 a.a.
437 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
|
|
Q6B856
(TBB2B_BOVIN) -
Tubulin beta-2B chain from Bos taurus
|
|
|
|
Seq: Struc:
|
 |
 |
 |
445 a.a.
421 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Med Chem
61:1031-1044
(2018)
|
|
PubMed id:
|
|
|
|
|
| |
|
Quinazolinone-Based Anticancer Agents: Synthesis, Antiproliferative SAR, Antitubulin Activity, and Tubulin Co-crystal Structure.
|
|
W.Dohle,
F.L.Jourdan,
G.Menchon,
A.E.Prota,
P.A.Foster,
P.Mannion,
E.Hamel,
M.P.Thomas,
P.G.Kasprzyk,
E.Ferrandis,
M.O.Steinmetz,
M.P.Leese,
B.V.L.Potter.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Quinazolinone-based anticancer agents were designed, decorated with functional
groups from a 2-methoxyestradiol-based microtubule disruptor series,
incorporating the aryl sulfamate motif of steroid sulfatase (STS) inhibitors.
The steroidal AB-ring system was mimicked, favoring conformations with an N-2
substituent occupying D-ring space. Evaluation against breast and prostate tumor
cell lines identified 7b with DU-145 antiproliferative activity
(GI50300 nM). A preliminary structure-activity relationship afforded
compounds (e.g., 7j GI5050 nM) with activity exceeding that of the
parent. Both 7b and 7j inhibit tubulin assembly in vitro and colchicine binding,
and 7j was successfully co-crystallized with the αβ-tubulin heterodimer as the
first of its class, its sulfamate group interacting positively at the colchicine
binding site. Microtubule destabilization by 7j is likely achieved by preventing
the curved-to-straight conformational transition in αβ-tubulin. Quinazolinone
sulfamates surprisingly showed weak STS inhibition. Preliminary in vivo studies
in a multiple myeloma xenograft model for 7b showed oral activity, confirming
the promise of this template.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
| | |